Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Onco-Innovations Ltd. (ONCO.CN)
Calgary, AB, CA
Onco-Innovations Ltd. is a Canadian biotechnology company primarily focused on pioneering cancer research and developing oncology treatments. A significant offering in their portfolio is ONC010, a product specifically designed for use in cancer therapies. This enterprise was founded on September 16, 2021, and conducts its operations from its headquarters located in Calgary, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +12.75% | +4.55% | -11.54% | +64.29% | -31.55% | -14.81% | -20.69% | +76.92% | +76.92% | +76.92% | +76.92% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-180,764.5%
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'25: -1,634.0%
-
Share dilution Biotechnology: -3.4%+0.0% ★
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'25: 0.00×
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fadia Saad | Consultant | — | — |
| Frederick West | Technology Transfer Advisor | — | — |
| Nico Mah | Chief Financial Officer & Corporate Secretary | — | male |
| Thomas O'Shaughnessy | Chief Executive Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ONCO.CN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
